Advertisement
Sunday, Sep 26, 2021
Outlook.com
Outlook.com

Serum Institute Seeks Emergency Authorisation For Covid-19 Vaccine In India

On Sunday, Pfizer had sought a similar clearance from the Drugs Controller General of India

Serum Institute Seeks Emergency Authorisation For Covid-19 Vaccine In India
Representational Image
Serum Institute Seeks Emergency Authorisation For Covid-19 Vaccine In India
outlookindia.com
2020-12-07T08:05:45+05:30

The Serum Institute of India (SII) on Sunday became the first indigenous company to apply to the Drugs Controller General of India (DCGI) seeking emergency use authorisation (EUA) for the Oxford Covid-19 vaccine in the country, official sources said.

A day earlier, the Indian arm of US pharmaceutical giant Pfizer became the first to seek a similar approval from India's drug regulator for its Covid-19 vaccine in the country, after securing similar clearances in the UK and Bahrain.

The phase-three clinical trial of the Oxford Covid-19 vaccine--Covishield, is being conducted by the Pune-based Serum Institute of India (SII), co-sponsored by the Indian Council of Medical Research (ICMR), in various parts of the country in addition to clinical studies being carried out by Oxford-AstraZeneca in the UK and Brazil.

Based on phase two and three clinical trial results, the SII with the help of the ICMR will pursue early availability of the vaccine for India, the country's apex health research body had said last month. According to the ICMR, the SII has already manufactured 40 million doses of the vaccine under the at-risk manufacturing and stockpiling license it obtained from the DCGI.

Official sources, citing the SII application said, the firm has stated that data from four clinical studies, two in the UK and one each in Brazil and India, shows that Covishield is highly effective against symptomatic and most importantly against severe Covid-19 infections.

The results are in line with other coronavirus vaccines and because of the huge disease burden, Covishield is predicted to alleviate substantial Covid-19 mortality and morbidity, the firm is learnt to have said.

"In terms of safety, Covishield was well tolerated with respect to solicited adverse events and was not associated with an increased number of SAEs and deaths. A majority of solicited reactions were mild in severity and resolved without any sequelae. Therefore, Covishield is safe and well-tolerated and can be used effectively for prevention of Covid-19 in the targeted population. Thus, the benefit to risk ratio strongly supports the widespread use of Covishield," a source said quoting the application.

The SII has also submitted 12 batches of the vaccine to the Central Drugs Laboratory (CDL) in Kasauli for testing, a source said.

"In line with our philosophy we assure you that for Covid-19 vaccines also, we are committed to making our country 'aatmanirbhar' (self-reliant) and fulfilling our prime minister's clarion call of 'vocal for local' and 'making in India' for the world," stated the application signed by Prakash Kumar Singh, Additional Director, Government and Regulatory Affairs at Serum Institute of India (SII).

In view of all these facts and unmet medical needs in the interest of the public at large to save millions of people in the country and across the globe, early availability of a vaccine against Covid-19 is a necessity, the application further stated.
"So, in the national interest, we request you to grant us emergency use authorisation of Covishield based on our application and in view of immediate need for a safe, effective, programmatically suitable and affordable vaccine for our country," the application read.

According to sources, this vaccine is logistically feasible for distribution in the country's urban and rural regions as it can be stored at two to eight degrees Celsius, which is an ideal temperature for being kept in cold storages in the country.

As a rapid regulatory response, the DCGI on August 2 had given nod to SII for conducting the combined phase two and three human clinical trials of the Oxford Covid-19 vaccine in the country.

Advertisement

Outlook Newsletters

Advertisement

Read More from Outlook

7 New Faces Likely In Punjab Cabinet; 5 Amarinder Singh Loyalists May Face Axe

7 New Faces Likely In Punjab Cabinet; 5 Amarinder Singh Loyalists May Face Axe

The new Punjab cabinet comprising 15 ministers will take oath on Sunday, the state’s Chief Minister Charanjit Singh Channi announced after having deliberations with the party high command.

Quad Not A Military Alliance, But Will Challenge China's Outreach In Indo-Pacific

Quad Not A Military Alliance, But Will Challenge China's Outreach In Indo-Pacific

Quad is to checkmate China’s growing profile as a nation giving humanitarian aid to nations across Asia and Pacific, and it wants to challenge China’s soft power bid in the region.

IPL 2021: Holder Heroics Not Enough For Sunrisers Hyderabad

IPL 2021: Holder Heroics Not Enough For Sunrisers Hyderabad

Holder took three wickets then scored an unbeaten 47 but still ended up on the losing side.

Police Reforms In India Are Long Overdue But No Government Has Made It A Priority

Police Reforms In India Are Long Overdue But No Government Has Made It A Priority

Several commissions were appointed from time to time at the state and central levels for reforms in the police, but their core recommendations were never accepted.

Advertisement